Olema Pharmaceuticals Inc. (NASDAQ:OLMA) went up by 8.52% from its latest closing price compared to the recent 1-year high of $60.27. The company’s stock price has collected -12.37% of loss in the last five trading sessions. Press Release reported on 11/22/21 that Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium
Is It Worth Investing in Olema Pharmaceuticals Inc. (NASDAQ :OLMA) Right Now?
Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for Olema Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $55.50, which is $33.33 above the current price. OLMA currently public float of 36.50M and currently shorts hold a 7.39% ratio of that float. Today, the average trading volume of OLMA was 377.93K shares.
OLMA’s Market Performance
OLMA stocks went down by -12.37% for the week, with a monthly drop of -18.16% and a quarterly performance of -25.43%, while its annual performance rate touched -52.94%. The volatility ratio for the week stands at 13.57% while the volatility levels for the past 30 days are set at 8.18% for Olema Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -15.00% for OLMA stocks with a simple moving average of -26.47% for the last 200 days.
Analysts’ Opinion of OLMA
Many brokerage firms have already submitted their reports for OLMA stocks, with JP Morgan repeating the rating for OLMA by listing it as a “Overweight.” The predicted price for OLMA in the upcoming period, according to JP Morgan is $52 based on the research report published on December 14th of the previous year 2020.
Jefferies, on the other hand, stated in their research note that they expect to see OLMA reach a price target of $70. The rating they have provided for OLMA stocks is “Buy” according to the report published on December 14th, 2020.
OLMA Trading at -19.36% from the 50-Day Moving Average
After a stumble in the market that brought OLMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.22% of loss for the given period.
Volatility was left at 8.18%, however, over the last 30 days, the volatility rate increased by 13.57%, as shares sank -17.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.70% lower at present.
During the last 5 trading sessions, OLMA fell by -12.37%, which changed the moving average for the period of 200-days by -56.92% in comparison to the 20-day moving average, which settled at $25.85. In addition, Olema Pharmaceuticals Inc. saw -53.89% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at OLMA starting from Horn Kinney, who sale 27,668 shares at the price of $26.88 back on Nov 10. After this action, Horn Kinney now owns 1,790 shares of Olema Pharmaceuticals Inc., valued at $743,716 using the latest closing price.
Harmon Cyrus, the CHIEF TECHNOLOGY OFFICER of Olema Pharmaceuticals Inc., sale 12,000 shares at $27.98 during a trade that took place back on Oct 19, which means that Harmon Cyrus is holding 1,051,546 shares at $335,794 based on the most recent closing price.
Stock Fundamentals for OLMA
The total capital return value is set at -12.78, while invested capital returns managed to touch -13.13. Equity return is now at value -18.60, with -18.30 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 74.62.